Skip to main content

Newamsterdam Pharma

NewAmsterdam Pharma Company NV is a Dutch clinical-stage biopharmaceutical company focused on the research, development, and commercialization of innovative oral therapies for metabolic diseases, prominently featuring obicetrapib, an advanced cholesteryl ester transfer protein (CETP) inhibitor designed for patients with elevated low-density lipoprotein cholesterol (LDL-C) at high risk of cardiovascular disease. The company conducts advanced clinical trials evaluating oral therapeutics intended to reduce cardiovascular morbidity when statin therapies are insufficient. Its core business operations encompass biopharmaceutical clinical research, drug formulation design, regulatory clinical trial execution, and commercial pharmaceutical strategy. As a clinical-stage biopharmaceutical enterprise, the company generates minimal commercial revenue and finances its ongoing operations through public equity offerings and strategic pharmaceutical collaborations. NewAmsterdam Pharma holds a pioneering market position in cardiovascular metabolic therapeutics. The company is headquartered in Naarden, Netherlands, and its common stock trades on the Nasdaq Global Select Market.

10 of the funds FundTelligence covers report a position in Newamsterdam Pharma.

Legal name
Newamsterdam Pharma Co NV
Sector
Health Care
Country
Netherlands
Funds holding it
10

Funds holding Newamsterdam Pharma

Showing the 8 largest of 10 funds holding it.

Loading...